Fundamentals of Drug Delivery
Wiley-Blackwell (Verlag)
978-1-119-76960-6 (ISBN)
Controlled drug delivery has the potential to significantly improve therapeutic outcomes, increase clinical benefits, and enhance the safety of drugs in a wide range of diseases and health conditions. »Fundamentals of Drug Delivery« provides comprehensive and up-to-date coverage of the essential principles and processes of modern controlled drug delivery systems. Featuring contributions by respected researchers, clinicians, and pharmaceutical industry professionals, this edited volume reviews the latest research in the field and addresses the many issues central to the development of effective, controlled drug delivery.
Divided in three parts, the book begins by introducing the concept of drug delivery and discussing both challenges and opportunities within the rapidly evolving field. The second section presents an in-depth critique of the common administration routes for controlled drug delivery, including delivery through skin, the lungs, and via ocular, nasal, and otic routes. The concluding section summarizes the current state of the field and examines specific issues in drug delivery and advanced delivery technologies, such as the use of nanotechnology in dermal drug delivery and advanced drug delivery systems for biologics.
This authoritative resource:
- Covers each main stage of the drug development process, including selecting pharmaceutical candidates and evaluating their physicochemical characteristics
- Describes the role and application of mathematical modelling and the influence of drug transporters in pharmacokinetics and drug disposition
- Details the physiology and barriers to drug delivery for each administration route
- Presents a historical perspective and a look into the possible future of advanced drug delivery systems
- Explores nanotechnology and cell-mediated drug delivery, including applications for targeted delivery and toxicological and safety issues
- Includes comprehensive references and links to the primary literature
Edited by a team of of internationally-recognized experts, »Fundamentals of Drug Delivery« is essential reading for researchers, industrial scientists, and advanced students in all areas of drug delivery including pharmaceutics, pharmaceutical sciences, biomedical engineering, polymer and materials science, and chemical and biochemical engineering.
Heather A.E. Benson, PhD is an Associate Professor at the Curtin Medical School, Curtin University, Australia, where she leads the Skin Delivery Research Group.
Michael S. Roberts, PhD is Professor of Therapeutics and Pharmaceutical Science at the University of South Australia, and a Professor of Clinical Pharmacology and Therapeutics at the University of Queensland, Australia.
Adrian C. Williams, PhD is Professor of Pharmaceutics and Research Dean at University of Reading, England, UK.
Xiaowen Liang, PhD is the UQ Development Fellow at The University of Queensland, Australia.
Preface xvii
Part I Product Design, the Essence of Effective Therapeutics 1
1 Challenges and Innovations of Controlled Drug Delivery 3
Heather A.E. Benson and Michael S. Roberts
1.1 Background 3
1.2 Parenteral Dosage Forms 3
1.2.1 Intravenous Route (IV) 4
1.2.2 Intramuscular Route (IM) 5
1.2.3 Subcutaneous Route (SC) 5
1.2.4 Other Parenteral Routes 5
1.3 Oral Route and Delivery Systems 6
1.4 Nasal Drug Delivery 6
1.5 Pulmonary Drug Delivery 7
1.6 Transdermal Drug Delivery 7
1.7 Ocular Drug Delivery 9
1.8 Drug Delivery System Development Process 11
1.9 Conclusion 12
References 12
2 Challenges in Design of Drug Delivery Systems 15
Narasimha Murthy
2.1 Drug Properties to be Considered in Design of Controlled Release Products 19
2.2 Physicochemical Factors that Need to be Considered in Design of CRDDS 19
2.2.1 Dose Size 19
2.2.2 MolecularWeight/Size 19
2.2.3 Aqueous Solubility 21
2.2.4 Lipid Solubility and Partition Coefficient 25
2.2.5 Physicochemical Stability 26
2.3 Biopharmaceutical Properties that Deserve Consideration in Design of Controlled Release Products 26
2.3.1 Biological Half-life 26
2.3.2 Absorption 27
2.3.3 Metabolism 30
2.3.4 Presystemic Clearance 32
2.3.5 Margin of Safety 32
2.3.6 Adverse Effects 33
2.3.7 Therapeutic Need 33
2.3.8 Role of Circadian Rhythm 34
2.4 Conclusion 35
References 35
3 Drug Delivery of the Future (?) 39
Adrian Williams
3.1 Introduction 39
3.2 Therapeutic Indicators 40
3.3 Drugs of the Future 43
3.4 Delivering the Drugs of the Future 45
3.5 A View to the Longer Term? 47
3.6 Conclusion 50
References 50
4 The Pharmaceutical Drug Development Process: Selecting a Suitable Drug Candidate 53
Lionel Trottet
4.1 The Oral Drug Candidate: How to Get There and Questions to Answer 53
4.2 Challenges for Selecting a Topical Drug Candidate 55
4.3 Percutaneous Flux as a Surrogate Measurement of Skin Tissue Concentration 57
4.4 Learnings from Past Topical Drug Development of Factors Affecting Efficacy 58
4.5 Dermal Pharmacokinetics/Pharmacodynamics 62
4.6 Assessment of Systemic Exposure 63
4.7 Screening Cascade Approach to Select a Dermal Drug Candidate 64
4.7.1 Efficacy (Lack of Target Engagement) 64
4.7.2 Developability 65
4.7.3 Local Safety 65
4.7.4 Systemic Safety 65
4.8 Opportunities for Repurposing Molecules into Dermally Active Treatments for Cosmeceutical or Pharmaceutical Approaches 66
4.9 Conclusion 66
References 67
5 Preformulation and Physicochemical Characterization Underpinning the Development of Controlled Drug Delivery Systems 73
Ronak Savla and Julien Meissonnier
5.1 When Is a Controlled Drug Delivery System Needed? 73
5.2 Optimizing Drug Characteristics 74
5.3 Defining the Product Profile 75
5.4 Preformulation and Physicochemical Characterization Underpinning Development of CDD 77
5.4.1 Feasibility and Risk Assessment 78
5.4.2 Solubility and Dissolution Rate 79
5.4.3 Permeability 82
5.4.4 Drug and Drug Product Particle Sizes 83
5.4.5 Solid-State Chemistry 84
5.4.5.1 Crystallinity and Polymorphism 84
5.4.5.2 Salts 85
5.4.6 Stability 85
5.4.7 Excipient Compatibility 86
5.4.8 Bulk Powder Properties 87
5.4.9 Drug Metabolism and Pharmacokinetic Modeling 88
5.4.9.1 Guiding the Design of CDD Dosage Forms 88
5.4.9.2 Establishing In Vitro-In Vivo Correlation (IVIVC) 89
5.4.9.3 Physiologically Based Pharmacokinetic (PBPK) Modeling Tools 89
5.5 Conclusion 89
References 89
6 Mathematical Models Describing Kinetics Associated with Controlled Drug Delivery Across Membranes 95
Annette L. Bunge
6.1 Introduction 95
6.1.1 General Description 95
6.1.2 Governing Equations 98
6.1.2.1 Differential Equations 98
6.1.2.2 Dimensionless Differential Equations 98
6.1.2.3 Initial and Boundary Conditions 99
6.1.3 Other Derived Quantities 100
6.1.4 Dimensionless Variables and Groups 102
6.2 Model Solutions 104
6.2.1 Type A Models -Well-Stirred Vehicle on One Membrane 104
6.2.1.1 Model A1 104
6.2.1.2 Model A2 107
6.2.1.3 Model A3 112
6.2.1.4 Model A4 116
6.2.1.5 Model A5 120
6.2.1.6 Model A6 121
6.2.1.7 Model A7 123
6.2.1.8 Model A8 124
6.2.1.9 Model A9 125
6.2.1.10 Model A9a 128
6.2.1.11 Model A9b 130
6.2.1.12 Model A10 132
6.2.1.13 Model A11 136
6.2.1.14 Model A12 137
6.2.1.15 Model A13 138
6.2.2 Type B Models - Unstirred Semi-infinite Vehicle on One Membrane 140
6.2.2.1 Model B1 140
6.2.2.2 Model B2 143
6.2.3 Type C -Well Stirred Vehicle on Two Membranes 145
6.2.3.1 Model C1 145
6.3 Solution Methods 149
6.3.1 Separation of Variables Solutions 150
6.3.1.1 Separating the Partial Differential Equation of N Independent Variables into N Ordinary Differential Equations 150
6.3.1.2 Choosing the Sign (Positive or Negative) on the Separation Constant 151
6.3.1.3 Finding the Constants of Integration and the Eigenvalues 152
6.3.1.4 Superposition 153
6.3.1.5 Finding the Remaining Constants of Integration 153
6.3.1.6 Guidelines for Using Separation of Variable Methods to Solve Partial Differential Equations 155
6.3.1.7 Methods for Making a Nonhomogeneous Partial Differential Equation or Nonhomogeneous Boundary Conditions Homogeneous 156
6.3.1.8 Choosing the Index Starting Value on the Sum of All Solutions (i.e. should n = 1 or 0?) 158
6.3.2 Laplace Transform Solutions 159
6.3.2.1 Using Laplace Transforms to Determine Lag Times, Steady-state Values and Other Derived Quantities 159
6.3.2.2 Inversion of Laplace Transformed Functions to Time Domain Functions by Method of Residues 161
6.3.2.3 Example A - Model A1 161
6.3.2.4 Example B - Model A10 165
6.3.3 Useful Identities 169
References 169
7 Understanding Drug Delivery Outcomes: Progress in Microscopic Modeling of Skin Barrier Property, Permeation Pathway, Dermatopharmacokinetics, and Bioavailability 171
Guoping Lian, Tao Chen, Panayiotis Kattou, Senpei Yang, Linyi Li, and Lujia Han
7.1 Introduction 171
7.2 Governing Equation 172
7.2.1 Homogenized Model 172
7.2.2 Microscopic Model 174
7.2.2.1 Solute Diffusion in SC Lipid 174
7.2.2.2 Solute Diffusion in SC Corneocytes 175
7.2.2.3 Solute Diffusion in Appendages 175
7.2.3 Numerical Methods 175
7.3 Input Parameters 176
7.3.1 SC Microstructure 176
7.3.2 SC Lipid-Water Partition 177
7.3.3 Diffusivity in SC Lipids 177
7.3.4 Binding to Keratin 179
7.3.5 Diffusivity in Corneocytes 181
7.3.6 Solute Diffusivity and Partition in Sebum 181
7.4 Application 183
7.4.1 Steady-State 183
7.4.2 Dermatopharmacokinetics 184
7.4.3 Systemic Pharmacokinetics 184
7.4.4 Shunt Pathway 185
7.5 Perspective 186
References 188
8 Role of Membrane Transporters in Drug Disposition 193
Hong Yang and Yan Shu
8.1 Introduction 193
8.2 Distribution of Major Drug Transporters in Human Tissues 194
8.2.1 Major Drug Transporters in the Intestine 194
8.2.1.1 Drug Transporters Expressed in the Apical (Luminal) Membrane 194
8.2.1.2 Drug Transporters Expressed in the Basolateral Membrane 196
8.2.1.3 Expression of Drug Transporters in Different Intestinal Regions 197
8.2.2 Major Drug Transporters in the Liver 197
8.2.2.1 Drug Transporters Expressed in the Apical Membrane of Hepatocytes 197
8.2.2.2 Drug Transporters Expressed in the Basolateral (Sinusoidal) Membrane of Hepatocytes 199
8.2.2.3 Drug Transporters Expressed in the Bile Duct Epithelia (Cholangiocytes) 199
8.2.3 Major Drug Transporters in the Kidney 199
8.2.3.1 Drug Transporters Expressed in the Apical Membrane of Proximal Tubule Cells 200
8.2.3.2 Drug Transporters Expressed in the Basolateral Membrane of Proximal Tubule Cells 200
8.2.4 Major Drug Transporters in the Central Nervous System (CNS) 201
8.2.4.1 Drug Transporters Expressed in the Capillary Endothelial Cells of BBB 201
8.2.4.2 Drug Transporters Expressed in the Choroid Plexus Epithelial Cells of BCSFB 202
8.2.5 Major Drug Transporters in Other Tissues 202
8.2.5.1 Drug Transporters Expressed in Placenta Villi Epithelial Cells (Syncytiotrophoblasts) 203
8.2.5.2 Drug Transporters Expressed in Mammary Glands 203
8.2.5.3 Drug Transporters Expressed in the Blood-Testis-Barrier (BTB) 204
8.3 Role of Drug Transporters in Drug Disposition 205
8.3.1 Role of P-gp in Drug Disposition 206
8.3.2 Role of BCRP in Drug Disposition 207
8.3.3 Role of BSEP in Drug-Induced Cholestatic Liver Injury 214
8.3.4 Role of MRPs (MRP2, MRP3, and MRP4) in Drug Disposition 214
8.3.5 Role of OATPs (OATP1B1, OATP1B3, and OATP2B1) in Drug Disposition 215
8.3.6 Role of OATs (OAT1 and OAT3) in Drug Disposition 216
8.3.7 Role of OCTs (OCT1 and OCT2)/MATEs (MATE1 and MATE2-K) in Drug Disposition 217
8.4 Closing Remarks 218
References 219
9 Advanced Drug Delivery Systems for Biologics 231
May W. Joraholmen, Selenia Ternullo, Ann M. Holsaeter, Goril E. Flaten, and Natasa Skalko-Basnet
9.1 Introduction 231
9.2 Considerations in Biologics Product Development 232
9.2.1 Challenges Specific to the Route of Administration 232
9.2.2 Challenges Related to Parenteral Administration 232
9.2.3 Optimization of Dosage Regimens 232
9.3 Administration Routes for Biologics Delivery 233
9.3.1 Parenteral Route 233
9.3.2 Oral Route 234
9.3.3 Buccal Route 235
9.3.4 Sublingual Route 236
9.3.5 Pulmonary Route 236
9.3.5.1 Additional Concerns in Pulmonary Delivery 237
9.3.6 Intranasal Route 237
9.3.7 Trans(dermal) Delivery 238
9.3.7.1 Gene Delivery 239
9.3.7.2 Vaccine Delivery 240
9.3.7.3 Protein Delivery 241
9.3.8 Dermal Delivery of Growth Hormones 241
9.3.9 Vaginal Route 245
9.4 Conclusion 249
References 249
10 Recent Advances in Cell-Mediated Drug Delivery Systems for Nanomedicine and Imaging 261
Li Li and Zhi Qi
10.1 Introduction 261
10.2 Cell Types and Modification for Therapeutic Agent Delivery 262
10.2.1 Cell Types 262
10.2.1.1 Blood Cells 262
10.2.1.2 Stem Cells 265
10.2.1.3 Antigen Presenting Cells (APCs) 266
10.2.1.4 Cell Membranes 266
10.2.2 Cargo Loading Methods 267
10.3 Imaging and Tracking of Cell-Based Delivery Systems 268
10.3.1 MRI 269
10.3.2 PET 270
10.3.3 X-Ray Imaging 270
10.3.4 Multimodal Imaging Techniques 270
10.4 Cell-Mediated Drug Delivery Systems for Disease Treatment 270
10.4.1 Cancer Therapy 270
10.4.2 Immunotherapy 270
10.4.3 Brain-Related Diseases 272
10.4.4 Inflammatory Diseases 272
10.4.5 Theranostic Application 273
10.4.6 Others 273
10.5 The Mechanism of Cell-Mediated Delivery Systems for the Cell Therapies 273
10.5.1 Detoxification 274
10.5.2 Adhesive Mechanism 275
10.5.3 Homing Mechanism 276
10.6 The Administration Approach of Cell-Assist Drug Delivery System 276
10.7 Clinical Application of Cell-Based Delivery Systems 277
10.8 Conclusion and Outlook 277
References 278
11 Overcoming the Translational Gap - Nanotechnology in Dermal Drug Delivery 283
Christian Zoschke and Monika Schafer-Korting
11.1 Nanotechnology - Failure or Future in Drug Delivery? 283
11.2 Identification of the Clinical Need 284
11.3 Nanoparticle Design and Physicochemical Characterization 287
11.4 Biomedical Studies 292
11.4.1 Atopic Dermatitis 292
11.4.2 Psoriasis 293
11.4.3 Ichthyosis 294
11.4.4 Wound Healing 295
11.4.5 Infections 295
11.4.6 Skin Cancer 296
11.4.7 Alopecia Areata 297
11.5 Approaches to Fill the Translational Gaps in Nanotechnology 297
References 301
12 Theranostic Nanoparticles for Imaging and Targeted Drug Delivery to the Liver 309
Haolu Wang, Haotian Yang, Qi Ruan, Michael S. Roberts, and Xiaowen Liang
12.1 Introduction 309
12.2 The Types of Theranostic NPs 310
12.2.1 Lipid- and Polymer-Based NPs 310
12.2.2 Mesoporous Silica NPs 310
12.2.3 Bio-nanocapsules 311
12.2.4 Iron Oxide NPs 311
12.3 Mechanisms of NPs Targeting the Liver 311
12.3.1 Passive Targeting to the Liver 311
12.3.2 Active Targeting to the Liver 312
12.3.3 Strategies for Combining Passive and Active Targeting 313
12.4 NPs in Liver Target Imaging 313
12.4.1 NP-Based Contrast Agents in Liver MRI 313
12.4.2 NP-Based Contrast Agents in Liver CT Imaging 314
12.4.3 NPs for Near-Infrared Fluorescence Imaging in Liver 314
12.5 NPs for Therapeutic and Drug Delivery in Liver Disease 314
12.5.1 NP Delivery System in HCC 314
12.5.2 NP Delivery System in Non-tumoral Liver Disease 316
12.6 Theranostic NPs in Liver Diseases 316
12.7 Conclusions 320
References 321
13 Toxicology and Safety of Nanoparticles in Drug Delivery System 327
Klintean Wunnapuk
13.1 Introduction 327
13.2 Lipid-Based Nanocarrier: Liposomes 327
13.3 Cellular Uptake Mechanism of Liposomes 328
13.4 Biodistribution, Clearance and Toxicity of Liposomes 329
13.4.1 Effect of Lipid Compositions on Liposome Distribution and Blood Circulation 329
13.4.2 Effect of Surface Charge on Liposome Distribution and Blood Circulation 331
13.4.3 Effect of Size on Liposome Distribution and Blood Circulation 331
13.5 Application of Liposomes in Drug Delivery 332
13.6 Inorganic Nanocarrier: Carbon Nanotubes 334
13.7 Cellular Uptake Mechanism of Carbon Nanotubes 335
13.8 Biodistribution, Clearance, and Toxicity of Carbon Nanotubes 335
13.9 Application of Carbon Nanotubes in Drug Delivery 340
13.10 Conclusion 340
References 340
Part II Administrative Routes for Controlled Drug Delivery 347
14 Controlled Drug Delivery via the Ocular Route 349
Peter W.J. Morrison and Vitaliy V. Khutoryanskiy
14.1 Introduction 349
14.2 Physiology of the Eye 350
14.2.1 Ocular Membranes; Conjunctiva, Cornea, and Sclera 351
14.2.2 Internal Ocular Structures 352
14.2.3 Anterior Chamber, Lens, and Vitreous Body 353
14.3 Ocular Disorders 353
14.3.1 Periocular Disorders 353
14.3.2 Intraocular Disorders 354
14.4 Controlled Drug Delivery Systems 355
14.4.1 Formulation Strategies 356
14.4.2 Mucoadhesive Systems 356
14.4.3 Solution to Gel In Situ Gelling Systems 357
14.4.4 Penetration Enhancers 359
14.4.5 Contact Lenses and Ocular Inserts 362
14.4.6 Intraocular Systems (Implants, Injectables, and Degradable Microparticles) 364
14.4.7 Phonophoresis and Ionophoresis 365
14.4.8 Topical Prodrugs 366
14.4.9 Microneedle Systems 366
14.5 Conclusions 367
References 368
15 Controlled Drug Delivery via the Otic Route 375
Jinsong Hao and S. Kevin Li
15.1 Introduction 375
15.2 Anatomy and Physiology of the Otic Route 375
15.2.1 Anatomy of the Otic Route 375
15.2.2 Barriers Relevant to Inner Ear Drug Delivery 376
15.2.2.1 Blood Labyrinth Barrier 376
15.2.2.2 Round Window Membrane 378
15.2.2.3 Oval Window 378
15.2.2.4 Eustachian Tube 378
15.2.2.5 Tympanic Membrane 379
15.3 Controlled Drug Delivery Systems 379
15.3.1 Intratympanic Administration 379
15.3.1.1 Silverstein MicroWick 380
15.3.1.2 Round Window Microcatheter ( Cath) 381
15.3.1.3 Gelfoam 381
15.3.1.4 Seprapack 381
15.3.1.5 Ozurdex as a RWM Implant 382
15.3.1.6 Propel Steroid-Eluting Stent 382
15.3.2 Trans-Oval Window Administration 382
15.3.3 Intracochlear Administration 383
15.3.3.1 Drug-Eluting Cochlear Implants 384
15.3.3.2 Microfluidic Reciprocating Reservoir 384
15.4 Conclusions 386
References 386
16 Controlled Drug Delivery via the Nasal Route 391
Barbara R. Conway and Muhammad U. Ghori
16.1 Introduction 391
16.2 Anatomy and Physiology of the Nose 391
16.3 Absorption from the Nasal Cavity 393
16.3.1 The Epithelial Barrier 393
16.3.2 Absorption 393
16.4 Mucus and Mucociliary Clearance 396
16.5 Drug Delivery Systems 397
16.5.1 Solutions and Suspensions 398
16.5.2 Mucoadhesive Polymers 399
16.5.2.1 In Situ Forming Nasal Gels 399
16.5.2.2 Nasal Inserts 407
16.5.2.3 Microspheres and Nanospheres 408
16.5.2.4 Liposomes 409
16.5.2.5 Microemulsions and Nanoemulsions 411
16.5.2.6 Combination/Hybrid Products and Others 411
16.5.3 The Nasal Route and the Blood-Brain Barrier 413
16.5.4 The Nasal Route for Vaccinations 417
16.5.5 In Vitro/in Vivo Models for Nasal Absorption 419
16.6 Conclusion 421
References 421
17 Controlled Drug Delivery via the Buccal and Sublingual Routes 431
Javier O. Morales, Parameswara R. Vuddanda, and Sitaram Velaga
17.1 Introduction 431
17.2 Buccal and Sublingual Physiology and Barriers to Drug Delivery 432
17.2.1 Saliva and Mucus 432
17.2.2 Buccal and Sublingual Epithelium and Permeation Barrier 432
17.3 Controlled Drug Delivery Systems 434
17.3.1 Tablets 434
17.3.2 Films 435
17.3.3 Gels, Ointments, and Liquid Formulations 436
17.3.4 Spray 436
17.3.5 Wafers 437
17.3.6 Lozenges 437
17.3.7 Advanced and Novel Drug Delivery Systems 437
17.4 Functional Excipients Used in Controlled Release Systems to Enhance Buccal and Sublingual Drug Bioavailability 438
17.4.1 Permeation Enhancers 438
17.4.2 Mucoadhesive Polymers 439
17.5 Conclusions 440
Acknowledgments 441
References 441
18 Controlled Drug Delivery via the Lung 447
Maria V. Ramirez-Rigo, Nazareth E. Ceschan, and Hugh D. C. Smyth
18.1 Introduction 447
18.2 The Relevant Physiology of the Route Including the Barriers to Drug Delivery 447
18.3 Controlled Drug Delivery Systems 449
18.3.1 Formulations 449
18.3.1.1 Dissolution Rate Controlled 449
18.3.1.2 Sustained Release Systems 449
18.3.1.3 Drug Complexes 453
18.3.1.4 Drug-Receptor Binding 454
18.3.1.5 Drug Conjugates 455
18.3.1.6 Drug-Polymer Matrix Particles 456
18.3.1.7 Large Porous Particles 457
18.3.1.8 Nanosystems 457
18.3.2 Devices 457
18.3.2.1 Controlling Lung Deposition Patterns 457
18.3.2.2 Nebulizers 458
18.3.2.3 Dry Powder Inhalers 459
18.3.2.4 Pressurized Metered-Dose Inhalers 460
18.4 Conclusions 462
Acknowledgments 462
References 462
19 Controlled Drug Delivery via the Vaginal and Rectal Routes 469
Jose das Neves and Bruno Sarmento
19.1 Introduction 469
19.2 Biological Features of the Vagina and Colorectum 470
19.2.1 Vagina 470
19.2.2 Colorectum 471
19.3 Controlled Drug Delivery Systems 472
19.3.1 Vaginal Route 474
19.3.1.1 Conventional Dosage Forms 474
19.3.1.2 Removable Drug Delivery Systems 481
19.3.1.3 Nanotechnology-based Drug Delivery Systems 484
19.3.2 Rectal Route 487
19.3.2.1 Dosage Forms 487
19.3.2.2 Nanotechnology-based Drug Delivery Systems 491
19.4 Conclusions 492
Acknowledgments 492
References 492
20 Controlled Drug Delivery into and Through Skin 505
Adrian Williams
20.1 Introduction 505
20.1.1 Human Skin Structure and Function 505
20.1.1.1 Biological Factors 505
20.1.1.2 Skin as a Physical Barrier 506
20.1.2 Drug Transport Through Skin 510
20.2 Controlled Drug Delivery into and Through Skin 511
20.2.1 Skin Barrier Modulation 511
20.2.1.1 Penetration Enhancers 512
20.2.1.2 Ablation 513
20.2.2 Controlled Release Transdermal and Topical Systems 513
20.2.2.1 Supersaturation 514
20.2.2.2 Reservoir Formation 516
20.2.2.3 Film Forming Systems 516
20.2.2.4 Vesicles 517
20.2.2.5 Particles 518
20.2.3 Device-Based Controlled Delivery 520
20.2.3.1 Iontophoresis 521
20.2.3.2 Sonophoresis 522
20.2.3.3 Electroporation 523
20.2.3.4 Microneedles 523
20.2.3.5 Heat 524
20.2.3.6 Other Devices 525
20.3 Combination Approaches 526
20.4 Conclusions 526
References 527
Index 533
| Erscheinungsdatum | 16.12.2021 |
|---|---|
| Verlagsort | Hoboken |
| Sprache | englisch |
| Maße | 177 x 264 mm |
| Gewicht | 1220 g |
| Einbandart | gebunden |
| Themenwelt | Medizin / Pharmazie ► Pharmazie |
| Naturwissenschaften ► Chemie | |
| Technik ► Maschinenbau | |
| Technik ► Umwelttechnik / Biotechnologie | |
| Schlagworte | Medikamentenabgabe |
| ISBN-10 | 1-119-76960-4 / 1119769604 |
| ISBN-13 | 978-1-119-76960-6 / 9781119769606 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
